Session 2: Advances in Psychophramacotherapy and Therapeutic Neuromodulation (MED-1029)
This course will review the concepts of evidence-based and measurement-based care and use them to develop optimal treatment strategies for major psychiatric disorders. Participants will recognize the significant number of patients who are insufficiently responsive to initial therapeutic interventions and will utilize available biological treatments optimally, including the first and second generation antipsychotics, antidepressants, mood stabilizing agents, anxiolytic/sedative hypnotics, and therapeutic neuromodulation. Participants will also develop treatment strategies based on the results of randomized-controlled and pragmatic trials tempered by the realities of clinical practice, and incorporate clinically relevant issues related to drug therapy including pharmacokinetics, pharmacodynamics, and drug interactions.
Monday Schizophrenia; Treatment of high risk, prodromal, first-onset, early course, and multi-episode patients; Results from pilot studies of novel therapies, randomized controlled, and pragmatic trials
Tuesday Recent changes in diagnosis and treatment of depressive disorders
Wednesday Therapeutic neuromodulation including electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation
Thursday Diagnosis and treatment of bipolar disorder; Results of STEP-BD trial; Diagnosis and drug therapy of anxiety disorders
Friday Opioid training: Diagnosis and management of opioid use disorders, problems regarding patient adherence to treatment, strategies to improve adherence
This advanced seminar is geared to mental health and health professionals.
(1) Analyze the role of evidence-based and measurement-based care in the development and use of treatment strategies for major psychiatric disorders
(2) Compare the relative value of various psychotropic agents for the treatment of major psychiatric disorders
(3) Discuss the emerging role of therapeutic neuromodulation in the treatment of psychiatric disorders
(4) Rate the importance of developing strategies which enhance patient adherence to treatment
(5) Identify strategies for the proper diagnosis and treatment of opioid use disorders
Philip Janicak, MD, is Adjunct Professor and consultant to the Neuromodulation Center in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, and APA Distinguished Life Fellow. Dr. Janicak’s primary research interests are the assessment and treatment of mood and psychotic disorders. He has conducted over 60 clinical trials and has been an NIMH grant awardee as both principal and co-investigator. He has authored, co-authored, or edited over 500 publications and is first author of Principles and Practice of Psychopharmacotherapy.
Dr. Janicak has the following disclosure: Otsuka Pharmaceuticals, honorarium for speaker's bureau. In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this for a maximum of 15 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 15 hours of participation for continuing education for allied health professionals.
APA Credit for Psychololgists:
The Medical College of Wisconsin is approved by the American Psychological Association to sponsor continuing education for psychologists. MCW maintains responsibility for this program and its content.
Attendance at all sessions is required, partial credit will not be awarded.
This activity contains content or processes that may be potentially stressful.
This course has been approved by the Wisconsin Medical Examining Board as meeting the requirements for the two-hour continuing education course on the responsible opioid prescribing guidelines per Med 13.03(3) of the Wisconsin Administrative Code. Reference Code # MED-1029.
The Medical College of Wisconsin is registered with the Illinois Department of Professional Regulation as a Continuing Education Sponsor for social workers (license number 159-000664).
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.
- 15.00 AAFPAAFP credit.
- 15.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 15.00 APAAPA credit.
- 15.00 Hours of ParticipationHours of Participation credit.
Registration prior to May 17, 2019 = $565 after May 17, 2019 = $615.00
Purchase an additional 5 DAY session and receive a $100.00 discount. Use coupon code: +DCSI
Please Note: The billing address entered at check out must match the address associated with the credit card used or your credit card will be declined. The Medical College of Wisconsin accepts MasterCard, VISA and Discover cards.
All registrations are assessed a $16 non-refundable processing fee.
Tuition includes course materials and continental breakfast.
Refund Policy: Refunds, minus a $50 administrative fee, may be obtained if requested in writing no later than 15 days prior to the beginning of each session. There will be no refunds thereafter.